Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NERV Stock Forecast 2026-2027
$4.31
Current Price
$186.51M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to NERV Price Targets
+16.0%
To High Target of $5.00
+4.4%
To Median Target of $4.50
-7.2%
To Low Target of $4.00
NERV Price Momentum
-8.3%
1 Week Change
+6.7%
1 Month Change
+101.4%
1 Year Change
+7.2%
Year-to-Date Change
-65.4%
From 52W High of $12.46
+274.8%
From 52W Low of $1.15
📊 TOP ANALYST CALLS
Did NERV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Minerva is one of their latest high-conviction picks.
Latest NERV Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, NERV has a neutral consensus with a median price target of $4.50 (ranging from $4.00 to $5.00). The overall analyst rating is N/A (N/A/10). Currently trading at $4.31, the median forecast implies a 4.4% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 16.0% upside. Conversely, the most conservative target is provided by Douglas Tsao at HC Wainwright & Co., suggesting a 7.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NERV Analyst Ratings
0
Buy
2
Hold
0
Sell
NERV Price Target Range
Low
$4.00
Average
$4.50
High
$5.00
Current: $4.31
Latest NERV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NERV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 6, 2025 | HC Wainwright & Co. | Douglas Tsao | Neutral | Maintains | $4.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $5.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $5.00 |
| Aug 7, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Maintains | $5.00 |
| May 2, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Maintains | $7.00 |
| Feb 27, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $11.00 |
| Aug 2, 2023 | HC Wainwright & Co. | Douglas Tsao | Neutral | Maintains | $11.00 |
| May 16, 2023 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $8.00 |
| May 2, 2023 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $8.00 |
| Mar 9, 2023 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $8.00 |
| Nov 10, 2022 | HC Wainwright & Co. | Douglas Tsao | Neutral | Downgrade | $N/A |
| Oct 17, 2022 | JMP Securities | Jason Butler | Market Perform | Downgrade | $N/A |
| Mar 4, 2022 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $5.00 |
| Jun 8, 2020 | HC Wainwright & Co. | Buy | Maintains | $10.00 | |
| Dec 19, 2019 | HC Wainwright & Co. | Buy | Reiterates | $20.00 | |
| Dec 19, 2019 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Dec 19, 2019 | JMP Securities | Market Outperform | Maintains | $18.00 | |
| Sep 25, 2019 | Chardan Capital | Buy | Initiates | $N/A | |
| Sep 18, 2019 | William Blair | Outperform | Initiates | $N/A | |
| May 31, 2019 | H.C. Wainwright | Buy | Initiates | $N/A |
Minerva Neurosciences Inc. (NERV) Competitors
The following stocks are similar to Minerva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NERV
Minerva Neurosciences
mkt cap
192.57M
Minerva Neurosciences Inc. (NERV) Financial Data
Minerva Neurosciences Inc. has a market capitalization of $186.51M with a P/E ratio of 2.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -5.6%.
Valuation Metrics
Market Cap
$186.51M
Enterprise Value
$77.92M
P/E Ratio
2.5x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+40.8%
Current Ratio
4.9x
Debt/Equity
-1.7x
ROE
-5.6%
ROA
-25.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Minerva Neurosciences Inc. (NERV) Business Model
About Minerva Neurosciences Inc.
What They Do
Develops therapies for central nervous system disorders.
Business Model
The company focuses on the research and development of innovative drugs targeting serious mental health conditions, such as schizophrenia and depressive disorders. It generates revenue through the commercialization of these therapeutic products, leveraging clinical trials and partnerships with academic institutions to advance its pipeline.
Additional Information
Minerva Neurosciences Inc. is positioned within the pharmaceutical industry and aims to enhance patient outcomes in mental health care. By utilizing cutting-edge technology and collaborating with medical researchers, it strives to address unmet medical needs in neuropsychiatric disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Dr. Remy Luthringer Ph.D.
Country
United States
IPO Year
2014
Website
www.minervaneurosciences.comMinerva Neurosciences Inc. (NERV) Latest News & Analysis
Latest News
Quick Summary
Dr. Inder Kaul, CMO of Draig Therapeutics, has joined the Board of Directors at Minerva Neuroscience and will consult on the development of roluperidone.
Why It Matters
Dr. Kaul's appointment could enhance Minerva's strategic direction and development of roluperidone, potentially boosting investor confidence and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
2 months ago
Quick Summary
Minerva Neurosciences, Inc. reported its Q3 2025 financial results and business updates, focusing on therapies for central nervous system disorders.
Why It Matters
Minerva Neurosciences' Q3 financial results could indicate progress or setbacks in its drug development, impacting stock performance and investor sentiment in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Minerva has secured $80 million upfront and may receive an additional $80 million through Tranche A warrants. The FDA has outlined a path for roluperidone's clinical development and NDA resubmission.
Why It Matters
Minerva's $80 million funding and FDA agreement for roluperidone's development signal financial stability and potential drug approval, enhancing investor confidence and future valuation prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The FDA has mandated a confirmatory study for roluperidone, indicating ongoing regulatory scrutiny for its use in treating negative symptoms of schizophrenia.
Why It Matters
The FDA's requirement for a confirmatory study on roluperidone may delay market entry, impacting potential revenue and stock valuations for the developing company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
8 months ago
Quick Summary
Minerva Neurosciences, Inc. (Nasdaq: NERV) reported Q1 2025 business updates and financial results, focusing on therapies for central nervous system disorders.
Why It Matters
Minerva Neurosciences’ financial results and business updates may indicate progress in drug development and potential market performance, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
10 months ago
Quick Summary
Minerva Neurosciences, Inc. (Nasdaq: NERV) reported its fourth quarter and full year financial results for 2024, focusing on therapies for central nervous system disorders.
Why It Matters
Minerva Neurosciences' financial results and business updates signal its progress in drug development, potentially impacting stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NERV Stock
What is Minerva Neurosciences Inc.'s (NERV) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Minerva Neurosciences Inc. (NERV) has a median price target of $4.50. The highest price target is $5.00 and the lowest is $4.00.
Is NERV stock a good investment in 2026?
According to current analyst ratings, NERV has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NERV stock?
Wall Street analysts predict NERV stock could reach $4.50 in the next 12 months. This represents a 4.4% increase from the current price of $4.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Minerva Neurosciences Inc.'s business model?
The company focuses on the research and development of innovative drugs targeting serious mental health conditions, such as schizophrenia and depressive disorders. It generates revenue through the commercialization of these therapeutic products, leveraging clinical trials and partnerships with academic institutions to advance its pipeline.
What is the highest forecasted price for NERV Minerva Neurosciences Inc.?
The highest price target for NERV is $5.00 from Douglas Tsao at HC Wainwright & Co., which represents a 16.0% increase from the current price of $4.31.
What is the lowest forecasted price for NERV Minerva Neurosciences Inc.?
The lowest price target for NERV is $4.00 from Douglas Tsao at HC Wainwright & Co., which represents a -7.2% decrease from the current price of $4.31.
What is the overall NERV consensus from analysts for Minerva Neurosciences Inc.?
The overall analyst consensus for NERV is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are NERV stock price projections?
Stock price projections, including those for Minerva Neurosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:44 AM UTC